The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03471065

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03471065
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03471065. Allocation not applicable; no masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2019-12-23 (actual). Results posted on 2021-01-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis
Condition
Aortic Valve Stenosis
Intervention (Device)
SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct03471065
Content hash
7a98837d5417455a6d834ef9b31dd93a90fb94e13250d22020253c9ca2debb7d